Table 4 Combination therapy of PP2A modulators
From: Altering phosphorylation in cancer through PP2A modifiers
Compound | Cancer Types | Therapeutic Combinations | References |
|---|---|---|---|
FTY720 | Cisplatin-resistant melanoma | Cisplatin, 5ʹFU, Oxaliplatin | [130] |
Acute myeloid leukemia | Venetoclax | [150] | |
Erythroleukemia | A-1331852 | ||
Colorectal cancer | Cisplatin, 5ʹFU, Oxaliplatin, Doxorubicin (DOX), Etoposide (VP16), SN-38 | ||
Gastric cancer | Cisplatin | [87] | |
CM-1231 | Acute myeloid leukemia | Venetoclax | [150] |
NSC49L | Colorectal Cancer | TRAIL | |
FOLFOX-resistant Colorectal Cancer | |||
LB-100 | Cisplatin-resistant ovarian carcinoma | Cisplatin | [128] |
Medulloblastoma | [144] | ||
Osteosarcoma | [129] | ||
Glioblastoma | Anti-CAIX CAR-T therapy, Temozolomide, Doxorubicin | ||
Pancreatic cancer | Doxorubicin | [151] | |
Hepatocellular carcinoma | [152] | ||
Pheochromocytoma | Temozolomide | [153] | |
JAK2-driven myeloproliferative neoplasms | Ruxolitinib | [154] | |
Forskolin | Acute myeloid leukemia | Idarubicin and Ara-c | [24] |
OP449 | Acute myeloid leukemia | Imatinib, Nilotinib, Dasatinib | [140] |
Chronic myeloid leukemia | |||
Prostate cancer | Enzalutamide | [155] | |
Bortezomib | Hepatocellular carcinoma | CS-1008 | [156] |
Okadaic acid (OA) | Chronic myeloid leukemia | Dasatinib | [157] |
Lung cancer | Hematain | [158] | |
Ethoxysanguinarine (ESG) | Lung cancer | Cisplatin | [94] |
SMAPs | TKI-resistant advanced lung adenocarcinoma | TKI Afatinib | [61] |
Acute myeloid leukemia | Venetoclax | [150] | |
Breast cancer | Fluphenazine (Flu) | [132] | |
Lung cancer | |||
Melanoma | |||
Pancreatic ductal carcinoma | INK128 | [159] | |
Heterogenous Glioblastoma | UCN-01, MK-2206 | [66] | |
Medulloblastoma | |||
High-grade serous carcinoma (HGSC) | Olaparib | [133] |